Topic

Julian Upton is Pharmaceutical Executive’s European and Online Editor. He can be reached at 

Articles

As we wait for a COVID-19 vaccine, pharma is looking to blockchain technology to prepare for the major supply-chain obstacles to come.

Vaccine Supply: Trusting in Blockchain

Peter Kohut is Director of Drug Safety at Arriello and an experienced EU QPPV. He began his career in biochemical research, before entering the pharmaceutical industry where he has worked in both clinical trials and post-marketing safety roles. Arriello is a global provider of innovative, high-impact market access, regulatory affairs & pharmacovigilance solutions and services for pharma and biotech firms primarily in Europe and North America.

Peter Kohut analyses the findings of a survey on how life sciences companies are capitalizing on opportunities to transform workload and data quality management using the latest smart technology.

Streamlining Pharmacovigilance: Why the Inertia?

Vijesh Unnikrishnan is a principal in ZS’s digital and connected health (DCH) practice. Ganesh Vedarajan leads ZS’s strategy and transformation practice.

The recent merger of Teledoc and Livongo  into a $38 billion titan proves that the market sees opportunity in health tech. Could it be an inflection point in our race towards a digital-first care model, or is this an experiment ahead of its time? 

The Teladoc-Livongo Merger: Life Science Manufacturers’ Darwinian Moment

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

EXUMA Biotech's Dr. Greg Frost talks about his work making CAR-T cell therapy readily accessible and affordable.

Expanding Access to CAR-T: Dr. Greg Frost

Their application for security and anti-counterfeiting purposes continues to evolve, especially in combination with digital technology.

Holograms as Industry Tool Here to Stay

Dr. Volkmar Weckesser is Chief Information Officer, CENOTGENE GMBH

When approached correctly, drug development in the rare disease space can be quite successful – especially when powerhouses across the industry join forces and leverage the power of data to help drive potential treatment options.

Success Factors for Orphan Drug Development

How companies are leveraging Real Word Evidence to evaluate therapies under real world conditions in a broader population at a lower cost than using Randomized Clinical Trials.

Unlock Real World Evidence with Pragmatic Data Governance and Quality Practices

Trista Bridges is Partner, Edge+ Management Consulting Marketing; Gilda Sala is Founding Partner,

; and Rune Sølvsteen is Managing Partner, Defacto Partners Limited.

A new patient journey is emerging. Gilda Sala, Trista Bridges, and Rune Soelvsteen offer easy steps to future-proof your company’s approach.

Are You Ready for the Telemedicine Revolution?

Stephanie Hill has over 20 years of experience in the industry and has since worked across multiple therapy areas, supporting patients with long term conditions and rare diseases. Since 2016, Steph has been supporting the design, implementation and management of patient support programmes for key brand launches across the EU.She is now Head of Patient Solutions for Ashfield UK.

Stephanie Hill looks at the efforts made by patient solutions providers in the UK to build and support services outside the hospital environment during the pandemic.

COVID-19: Expanding Remote Patient Services during Lockdown

Accelerator program seeks to nourish promising innovation. 

Technology